Aktis Oncology to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Aktis Oncology (NASDAQ:AKTS)/b) announced that President and CEO Matthew Roden, Ph.D., will present at the in New York on Wednesday, June 3, 2026, at 4:20 p.m. ET.
A live webcast and 90-day replay will be available on the company’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – AKTS
In the May 28 session, AKTS gained 2.56%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Clinical imaging data | Positive | +6.4% | First-in-human imaging and dosimetry data for AKY-2519 with robust uptake. |
| May 11 | Earnings and pipeline | Positive | +8.0% | Q1 2026 results showing strong cash position and advancing clinical programs. |
| May 6 | Conference presentation | Neutral | +3.0% | Announcement of presentation at BofA Securities Health Care Conference. |
| May 4 | Trial initiation | Positive | +2.3% | Initiation of Phase 1b trial for AKY-2519 in mCRPC patients. |
| May 3 | Sector M&A mention | Neutral | -2.2% | Article on Candid Therapeutics’ acquisition noting Aktis’s IPO among examples. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including clinical and corporate updates, has generally coincided with positive next-day price reactions.
Over the past month, Aktis Oncology has reported multiple milestones, including initiation of a Phase 1b trial for AKY-2519 on May 4 and first-in-human imaging and dosimetry data on May 21, both followed by positive price moves. Its first public-company earnings report on May 11 also saw a favorable reaction. Conference presentation announcements, such as the BofA event on May 6, have likewise aligned with modest gains, framing today’s Jefferies conference news within an ongoing momentum phase.
Key Terms
radiopharmaceuticals medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will take place on Wednesday, June 3, 2026, at 4:20 p.m. ET.
A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Aktis’ miniprotein radioconjugate platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end supply chain, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second clinical-stage pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung, colorectal, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis’ miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit www.aktisoncology.com.
Media contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com
Investor contact:
Precision AQ
Alex Lobo
212-698-8802
Alex.lobo@precisionaq.com
